home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

101.27 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

26 27 Next >

Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists

April 23, 2024

From Incyte and Escient Pharmaceuticals

Via Business Wire

When you look at NASDAQ:INCY, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗

April 17, 2024

Don't overlook INCYTE CORP (NASDAQ:INCY)—it's a hidden gem with strong fundamentals and an attractive price tag.

Via Chartmill

Incyte to Report First Quarter Financial Results

April 11, 2024

From Incyte

Via Business Wire

Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion ↗

April 06, 2024

ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates...

Via Talk Markets

NASDAQ:INCY stands out as a growth opportunity that won't break the bank. ↗

April 05, 2024

NASDAQ:INCY is showing good growth, while it is not too expensive.

Via Chartmill

NASDAQ:INCY, a growth stock which is not overvalued. ↗

March 15, 2024

Despite its growth, NASDAQ:INCY remains within the realm of affordability.

Via Chartmill

Incyte Stock: A Deep Dive Into Analyst Perspectives (8 Ratings) ↗

March 12, 2024

Via Benzinga

Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

April 01, 2024

From Incyte

Via Business Wire

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

March 29, 2024

From Incyte

Via Business Wire

For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals. ↗

March 26, 2024

INCYTE CORP (NASDAQ:INCY) is an undervalued gem with solid fundamentals.

Via Chartmill

Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead ↗

March 11, 2024

Don't fall for the siren song of penny stocks. Rather, fill your portfolio with companies that have a proven track record of success.

Via InvestorPlace

NASDAQ:INCY stands out as a stock that provides good value for the fundamentals it showcases. ↗

March 04, 2024

INCYTE CORP (NASDAQ:INCY): good value for what you're paying.

Via Chartmill

The Analyst Verdict: Incyte In The Eyes Of 8 Experts ↗

February 14, 2024

Via Benzinga

Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa

March 10, 2024

From Incyte Corporation

Via Business Wire

Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis

March 10, 2024

From Incyte

Via Business Wire

3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise ↗

March 07, 2024

Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth.

Via InvestorPlace

New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting

March 04, 2024

From Incyte

Via Business Wire

Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI

February 29, 2024

From Incyte

Via Business Wire

Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease

February 27, 2024

From Incyte

Via Business Wire

7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff ↗

February 26, 2024

Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off.

Via InvestorPlace

NASDAQ:INCY stands out as a growth opportunity that won't break the bank. ↗

February 22, 2024

For those who appreciate growth without the sticker shock, INCYTE CORP (NASDAQ:INCY) is worth considering.

Via Chartmill

Exit Now! 3 Biotech Stocks to Sell in February 2024 ↗

February 21, 2024

These biotech stocks to sell represent incredibly risky bets, amidst the sector's volatility and looming economic unpredictability.

Via InvestorPlace

Incyte to Present at Upcoming Investor Conference

February 15, 2024

From Incyte

Via Business Wire

Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities

February 13, 2024

From Incyte

Via Business Wire

Despite its impressive fundamentals, NASDAQ:INCY remains undervalued. ↗

February 12, 2024

INCYTE CORP (NASDAQ:INCY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

Pancreatic Cancer Treatments Poised for Major Advances in 2024

February 07, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INCY),(NASDAQ:TNGX),(NASDAQ:RYZB),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Earnings Scheduled For February 13, 2024 ↗

February 13, 2024

Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million.

Via Benzinga

Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B ↗

February 06, 2024

Novartis' €2.7 billion public takeover offer for MorphoSys, unlocking a promising oncology pipeline with pelabresib and tulmimetostat.

Via Benzinga

Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion ↗

February 05, 2024

Novartis will add to its cancer treatment pipeline with via the German biotech.

Via Investor's Business Daily

Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)

February 05, 2024

From Incyte

Via Business Wire

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

26 27 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com